您好,欢迎来到佐思信息
全国服务热线:
400-009-0050
佐思信息专注支持企业决策

联系我们

400-009-0050

北京热线:010-82863481
13436696826
上海热线:021-64871266
021-64872612
传 真: 010-82601570
021-64872324

您当前的位置:首页>>研究报告>>药物综合

全球药品批发及销售市场2012-2022年研究报告
Pharma Wholesale and Distribution Market: World Outlook 2012-2022

全球药品批发及销售市场2012-2022年研究报告
【报告编号】:No.2705
【发布时间】:2012-06
【关 键 字】:药品批发   药品销售   
【报告页数】:157页
【报告价格】:电子版:1699英镑
【交付方式】:Email发送或EMS快递
【订购热线】:


400-009-0050(全国24小时服务)
北京:010-82863481 13436696826
上海:021-64871266 021-64872612

报告目录下载订购协议下载在线咨询

    专业、专注于为企业提供真正有价值的全球市场调查信息,是我们的使命。我们是中国第一家汇集全球众多行业研究机构研究成果的平台,致力于为企业决策提供最有效的市场资讯,特别是为中国企业了解和进入国际市场迈出第一步,提供全面的信息参考,我们跨越语言及时间的障碍,在信息爆炸的当下,努力为客户提供最有价值的全球产业资讯。我们公司也拥有独立的研究机构,聚焦于中国市场的研究,为国内外企业在中国市场大展宏图提供市场研究支持。

• 我们在全球的合作伙伴>>• 我们的研究中心>>

  • 英文摘要
  • 中文摘要
  • 索取简版报告
  • 药物综合行业的相关报告

Abstract

Report Details

image1

Your guide to trends and revenue potential in pharma wholesaling and distribution

Where is the pharmaceutical wholesale and distribution (W&D) industry heading? Visiongain's report shows you potential revenues and trends to 2022, discussing data, opportunities and prospects.
This new study investigates the W&D industry and its market environment. It lets you discover projected revenues at overall world market, main submarket, company and national level to 2022.
You see forecasts of world-level submarkets to 2022, finding potential revenue:
  • Original-branded drugs
  • Generic drugs.
How will 11 leading countries perform to 2022? You find W&D revenue forecasts, as well as discussions of what will drive and restrain those national markets:
  • US
  • Japan
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • China
  • Brazil
  • Russia
  • India.
You also find a revenue forecast to 2022 for the overall European W&D market.
Our study lets you assess the worldwide industry and market, seeing trends and outlooks. You find discussions of pharma supply issues such as these:
  • Prospects for the pharma distribution chain from 2012 onwards
  • Roles of pharmaceutical wholesalers
  • Full-line wholesalers (FLWs)
  • Short-line wholesalers (SLWs)
  • Secondary wholesalers
  • Direct-to-pharmacy distribution
  • Pharmacy benefit managers
  • Generating revenue and profit
  • Emerging national markets
  • Globalisation and increased demand for medicines.
The report also discusses these activities:
  • Forward buying
  • Fee-for-service activities
  • Serialisation for wholesalers
  • Specialty pharmaceuticals
  • Industry consolidation
  • Inventory management agreements and discounts
  • State-funded healthcare, reimbursements and clawbacks
  • Parallel trade and related issues
  • Impact of recent regulatory changes
  • Supermarket pharmacies, chain pharmacies and vertical integration
  • Pedigree legislation and using the supply chain to combat drug counterfeiting.

Market value for 2014 and prospects for the future

What does the future hold? The pharma industry and its supply chain partners will increase revenues from 2012 to 2022. Overall world revenue for wholesale and distribution activities will reach $747bn in 2014, the report forecasts.
What are companies doing? Our work profiles nine leading W&D organisations and investigates their revenue-generating prospects to 2022:
  • McKesson
  • Cardinal Health
  • AmerisourceBergen
  • The PHOENIX Group
  • Alfresa Holdings
  • Celesio
  • Alliance Boots
  • Suzuken
  • Medipal.
The scope of the field widens, with organisations collaborating and expanding their businesses. Our investigation shows you commercial possibilities.
Increased unit sales of generic drugs will restrain revenue growth, as will direct-to-pharmacy distribution. Demand for specialty pharma products will augment sales, the study also finds.
There will be increasing dependence on emerging countries to 2022, with their fast-rising drug sales. Developed countries hold promise too.
New products - novel small molecules, generics and biologics - will stimulate the pharma sector. Many opportunities for rising drug sales exist, with high, growing W&D revenues possible from 2012 to 2022. Our report shows you and explains.

Forecasts, market shares, developmental trends, commercial news and discussions

In visiongain's study you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), company profiles and commercial developments. You receive 62 tables, 41 charts and two research interviews.

Eight ways Pharma Wholesale and Distribution Market: World Outlook 2012-2022 helps you

In particular, our report gives you the following knowledge on the topic:
  • Find potential revenues to 2022 for the overall world market and submarkets
  • Discover projected revenue trends to 2022 for nine leading companies
  • See market forecasting to 2022 for the US, Japan, EU5 countries, Brazil, Russia, China and India
  • Assess leading companies, and other players, discovering activities and outlooks
  • Review issues and events in the industry and market - emerging trends
  • Investigate competition and opportunities influencing unit sales and revenues
  • Find out what will stimulate and restrain the industry and market
  • View opinions from the industry, reading interviews from our survey.
There, you discover quantitative and qualitative analyses with independent predictions. You receive information that only our report contains, staying informed on business intelligence.
Without our report you could miss out on information that your competitors use.

Gain research and analysis now for the supply of medicines

Our study is for everybody needing industry and market analyses for the supply of pharmaceuticals. You find data, predictions and answers there. Please order that report now.

Table of Contents

1. Executive Summary

  • 1.1 Overview of the Study
  • 1.2 Chapter Breakdown
  • 1.3 Research and Analysis Methods

2. Introduction to the Market

  • 2.1 The Role of Pharmaceutical Wholesalers
    • 2.1.1 Full-Line Wholesalers (FLWs)
    • 2.1.2 Short-Line Wholesalers (SLWs)
  • 2.2 The Chain of Distribution
    • 2.2.1 Secondary Wholesalers
    • 2.2.2 Direct-to-Pharmacy
    • 2.2.3 Pharmacy Benefit Managers
  • 2.3 Generating Revenue and Profit
    • 2.3.1 Forward Buying
    • 2.3.2 Fee-for-Service
    • 2.3.2.1 Inventory Management Agreements
    • 2.3.3 Discounts
    • 2.3.4 Reimbursement and Wholesalers
    • 2.3.5 Clawback
    • 2.3.6 Parallel Trade

3. The World Pharmaceutical Wholesale and Distribution Market, 2012-2022

  • 3.1 The World Market in 2011
  • 3.2 World Market Forecast, 2012-2022
  • 3.3 Branded and Generic Drugs
    • 3.3.1 Branded and Generic Drugs: Revenue Generation, 2011
    • 3.3.2 Branded and Generic Drugs: Revenue Forecasts, 2012-2022

4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2012-2022

  • 4.1 The US
    • 4.1.1 An Increase in Fee-for-Service Activity
    • 4.1.2 US Market Forecast, 2012-2022
  • 4.2 Europe
    • 4.2.1 Differences between the US and Europe
      • 4.2.1.1 State-Funded Healthcare and Reimbursement
    • 4.2.2 Europe and Leading EU Countries: Market Forecasts, 2012-2022
    • 4.2.3 Germany
      • 4.2.3.1 Healthcare Reform
      • 4.2.3.2 Market Forecast, 2012-2022
    • 4.2.4 France
      • 4.2.4.1 Market Forecast, 2012-2022
    • 4.2.5 Spain
      • 4.2.5.1 Market Forecast, 2012-2022
    • 4.2.6 The UK
      • 4.2.6.1 Price Cuts
      • 4.2.6.2 Market Forecast, 2012-2022
    • 4.2.7 Italy
      • 4.2.7.1 Market Forecast, 2012-2022
  • 4.3 Japan
    • 4.3.1 Drug Pricing and Performance Fees
    • 4.3.2 Market Forecast, 2012-2022
  • 4.4 China
    • 4.4.1 Leading Companies
    • 4.4.2 Recent Market Developments
    • 4.4.3 Market Forecast, 2012-2022
  • 4.5 Brazil
    • 4.5.1 Leading Companies
    • 4.5.2 Market Forecast, 2012-2022
  • 4.6 Russia
    • 4.6.1 Market Trends
    • 4.6.2 Market Forecast, 2012-2022
  • 4.7 India
    • 4.7.1 Market Forecast, 2012-2022
  • 4.8 Concluding Comments

5. Leading Pharma Wholesalers and Distributors in 2012

  • 5.1 Revenue vs. Profit
    • 5.1.1 Profit Margins
  • 5.2 Leading Companies: Grouped Forecasts, 2012-2022
  • 5.3 McKesson
    • 5.3.1 Recent Performance
    • 5.3.2 Future Strategies
    • 5.3.3 Revenue Forecast, 2012-2022
  • 5.4 Cardinal Health
    • 5.4.1 Segment Reorganisation
    • 5.4.2 Recent Performance
    • 5.4.3 Future Strategies
    • 5.4.4 Revenue Forecast, 2012-2022
  • 5.5 AmerisourceBergen
    • 5.5.1 Recent Performance
    • 5.5.2 Future Strategies
    • 5.5.3 Revenue Forecast, 2012-2022
  • 5.6 The PHOENIX Group
    • 5.6.1 Recent Performance
    • 5.6.2 The Tamro Group 2011
    • 5.6.3 Future Strategies
    • 5.6.4 Revenue Forecast, 2012-2022
  • 5.7 Alfresa Holdings
    • 5.7.1 Recent Performance
    • 5.7.2 Future Strategies
    • 5.7.3 Revenue Forecast, 2012-2022
  • 5.8 Celesio
    • 5.8.1 Recent Performance
    • 5.8.2 Future Strategies
    • 5.8.3 Revenue Forecast, 2012-2022
  • 5.9 Alliance Boots
    • 5.9.1 Recent Performance
    • 5.9.2 Future Strategies
    • 5.9.3 Revenue Forecast, 2012-2022
  • 5.10 Suzuken
    • 5.10.1 Recent Performance
    • 5.10.2 Future Strategies
    • 5.10.3 Revenue Forecast, 2012-2022
  • 5.11 Medipal
    • 5.11.1 Recent Performance
    • 5.11.2 Future Strategies
    • 5.11.3 Revenue Forecast, 2012-2022

6. Qualitative Industry and Market Analyses, 2012-2022

  • 6.1 Strengths
    • 6.1.1 Large Companies Dominate the Market
    • 6.1.2 Wholesalers Do More than Deliver Drugs
      • 6.1.2.1 Pre-Wholesaling
  • 6.2 Weaknesses
    • 6.2.1 Counterfeiting
    • 6.2.2 Low Margins
  • 6.3 Opportunities
    • 6.3.1 Increased Demand for Pharmaceuticals
    • 6.3.2 Generics
    • 6.3.3 Globalisation
  • 6.4 Threats
    • 6.4.1 Direct-to-Pharmacy (DTP)
      • 6.4.1.1 DTP in Europe
      • 6.4.1.2 The UK
      • 6.4.1.3 Poland
      • 6.4.1.4 DTP in Australia
      • 6.4.1.5 Further Expansion
    • 6.4.2 Healthcare Budget Cuts
    • 6.4.3 Diversion and Re-importation
    • 6.4.4 Supermarket Pharmacies
      • 6.4.4.1 Case Study: Walmart

7. Pharmaceutical Wholesale Industry Trends in 2012

  • 7.1 Combating Counterfeit Medicines
    • 7.1.1 The US and E-Pedigree
    • 7.1.2 European Pedigree Legislation
    • 7.1.3 Anti-Counterfeiting Strategies in Other Markets
    • 7.1.4 Issues in Serialisation for Wholesalers
  • 7.2 Growth in Specialty Pharmaceuticals
  • 7.3 Industry Consolidation
  • 7.4 Chain Pharmacies and Vertical Integration
  • 7.5 Impact of Recent Regulatory Changes

8. Research Interviews

  • 8.1 Interview with Monika Derecque-Pois, Director General, European Association of Pharmaceutical Full-line Wholesalers (GIRP)
    • 8.1.1 Key Unmet Needs
    • 8.1.2 Impact of Recent Regulatory Changes
    • 8.1.3 Value-Added Services
    • 8.1.4 Use of Novel Technologies
  • 8.2 Interview with Geoff Mellor and Martin Sawer, British Association of Pharmaceutical Wholesalers (BAPW)
    • 8.2.1 Recent Regulatory Changes
    • 8.2.2 Use of Technology
    • 8.2.3 Fast-Growing Sectors?

9. Conclusions from the Study

  • 9.1 There Will Be Steady Growth in Developed National Markets
    • 9.1.1 Generics Will Threaten Revenues
    • 9.1.2 Manufacturers Will Deliver More Drugs Directly
    • 9.1.3 There Will Be Greater Demand for Specialty Medicines
  • 9.2 Growth Will Be Fastest in Emerging National Markets
    • 9.2.1 Consolidation Will Drive Growth
  • 9.3 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs
  • 9.4 Concluding Remarks

List of Tables

  • Table 2.1 Prevalence of the DTP Model in the UK, 2012
  • Table 3.1 World Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Table 3.2 World Pharmaceutical W&D Market: Drivers and Restraints, 2012-2022
  • Table 3.3 Branded and Generic Drugs: Revenue Forecasts ($bn), 2011-2022
  • Table 3.4 Main Patent Expiries, 2011-2014
  • Table 3.5 Branded Drugs: Revenue Forecast ($bn), 2011-2022
  • Table 3.6 Generic Drugs; Revenue Forecast ($bn), 2011-2022
  • Table 3.7 Percent Revenue Generation Forecast: Branded vs. Generics, 2011-2022
  • Table 4.1 Pharmaceutical Wholesale and Distribution Market: Sales ($bn) and Market Shares (%) by Country, 2011
  • Table 4.2 Pharmaceutical Wholesale and Distribution Market: Leading National Revenue Forecasts ($bn), 2011-2022
  • Table 4.3 US Market: Revenues ($bn) and Market Shares (%) by Company, 2011
  • Table 4.4 The US Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Table 4.5 US Market Drivers and Restraints, 2012-2022
  • Table 4.6 EU5 Pharmaceutical W&D Market by Country: Sales ($bn) and Market Shares (%), 2011
  • Table 4.7 Prominent Price Controls in Europe, 2012
  • Table 4.8 EU5 Pharmaceutical W&D Market: Forecasts ($bn), 2012-2022
  • Table 4.9 EU5 Market Drivers and Restraints, 2012-2022
  • Table 4.10 German Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Table 4.11 German Market Drivers and Restraints, 2012-2022
  • Table 4.12 French Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Table 4.13 French Market Drivers and Restraints, 2012-2022
  • Table 4.14 Spanish Pharmaceutical W&D Market Forecast ($bn), 2012-2022
  • Table 4.15 Spanish Market Drivers and Restraints, 2012-2022
  • Table 4.16 UK Pharmaceutical W&D Market Forecast ($bn), 2012-2022
  • Table 4.17 UK Market Drivers and Restraints, 2012-2022
  • Table 4.18 Italian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Table 4.19 Italian Market Drivers and Restraints, 2012-2022
  • Table 4.20 Proportions (%) of Population Aged Over 65 Years by Region, 2025 and 2050
  • Table 4.21 Japanese Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Table 4.22 Japanese Market Drivers and Restraints, 2012-2022
  • Table 4.23 Chinese Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Table 4.24 Chinese Market Drivers and Restraints, 2012-2022
  • Table 4.25 Brazilian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Table 4.26 Brazilian Market Drivers and Restraints, 2012-2022
  • Table 4.27 Russian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Table 4.28 Russian Market Drivers and Restraints, 2012-2022
  • Table 4.29 Indian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Table 4.30 Indian Market Drivers and Restraints, 2012-2022
  • Table 5.1 Leading W&D Companies: Revenues ($bn) and Market Shares (%), 2011
  • Table 5.2 Leading W&D Companies: Revenue Forecasts ($bn), 2011-2022
  • Table 5.3 W&D Market Leaders: Commercial Drivers and Restraints, 2012-2022
  • Table 5.4 McKesson Pharmaceutical Wholesale Revenue by Country ($bn), 2011
  • Table 5.5 McKesson Pharmaceutical Gross Profit Margin (%), 2009-2011
  • Table 5.6 McKesson Revenue Forecast ($bn), 2011-2022
  • Table 5.7 Cardinal Health Revenue Forecast ($bn), 2011-2022
  • Table 5.8 AmerisourceBergen Revenue Forecast ($bn), 2011-2022
  • Table 5.9 The PHOENIX Group: Wholesale Subsidiaries, 2010
  • Table 5.10 The Tamro Group, 2011
  • Table 5.11 The PHOENIX Group Revenue Forecast ($bn), 2011-2022
  • Table 5.12 Alfresa Wholesale Subsidiaries , 2011
  • Table 5.13 Alfresa Holdings Revenue Forecast ($bn), 2011-2022
  • Table 5.14 Celesio Wholesale Subsidiaries, 2010
  • Table 5.15 Celesio Wholesale Revenue ($bn) by Country, 2011
  • Table 5.16 Celesio Revenue Forecast ($bn), 2011-2022
  • Table 5.17 Alliance Boots Wholesale Revenue ($bn) by Country, 2011
  • Table 5.18 Alliance Boots Revenue Forecast ($bn), 2011-2022
  • Table 5.19 Suzuken Revenue Forecast ($bn), 2011-2022
  • Table 5.20 Medipal Revenue Forecast ($bn), 2011-2022
  • Table 6.1 SWOT Analysis of the World W&D Industry and Market, 2012-2022
  • Table 6.2 STEP Analysis of the World W&D Industry and Market, 2012-2022
  • Table 6.3 Strengths and Weaknesses of the DTP Model, 2012
  • Table 9.1 Overall Pharmaceutical Wholesale Revenue ($bn) and Market Shares (%) by Leading Country, 2011, 2015 & 2022

List of Figures

  • Figure 2.1 Traditional Routes of Drug Distribution, 2012
  • Figure 3.1 World Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Figure 3.2 Branded Drugs: Revenue Forecast ($bn), 2011-2022
  • Figure 3.3 Generic Drugs: Revenue Forecast ($bn), 2011-2022
  • Figure 3.4 Percent Revenue Generation Forecast: Branded vs. Generics, 2011-2022
  • Figure 4.1 World Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2011
  • Figure 4.2 World Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2015
  • Figure 4.3 World Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2022
  • Figure 4.4 US Market Shares (%) by Leading Company, 2011
  • Figure 4.5 US Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Figure 4.6 EU5 Pharmaceutical Wholesale and Distribution Market Shares (%) by Country, 2011
  • Figure 4.7 European W&D Market: Overall Revenue Forecast ($bn), 2011-2022
  • Figure 4.8 German Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Figure 4.9 French Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Figure 4.10 Spanish Pharmaceutical W&D Market Forecast ($bn), 2012-2022
  • Figure 4.11 UK Pharmaceutical W&D Market Forecast ($bn), 2012-2022
  • Figure 4.12 Italian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Figure 4.13 Population Proportions (%) Aged Over 65 by Region, 2025 and 2050
  • Figure 4.14 Japanese Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Figure 4.15 Chinese Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Figure 4.16 Brazilian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Figure 4.17 Russian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Figure 4.18 Indian Pharmaceutical W&D Market Forecast ($bn), 2011-2022
  • Figure 5.1 Leading W&D Companies: Market Shares (%), 2011
  • Figure 5.2 McKesson Pharmaceutical Wholesale Revenue (%) by Country, 2011
  • Figure 5.3 McKesson Pharmaceutical Gross Profit Margin (%), 2009-2011
  • Figure 5.4 McKesson Revenue Forecast ($bn), 2011-2022
  • Figure 5.5 Cardinal Health Revenue (%) by Company, 2011
  • Figure 5.6 Cardinal Health Revenue Forecast ($bn), 2011-2022
  • Figure 5.7 AmerisourceBergen Revenue Forecast ($bn), 2011-2022
  • Figure 5.8 The Tamro Group: Revenue Shares (%) by Country, 2011
  • Figure 5.9 The PHOENIX Group Revenue Forecast ($bn), 2011-2022
  • Figure 5.10 Alfresa Holdings Revenue Forecast ($bn), 2011-2022
  • Figure 5.11 Celesio Wholesale Revenue Shares (%) by Country, 2011
  • Figure 5.12 Celesio Revenue Forecast ($bn), 2011-2022
  • Figure 5.13 Alliance Boots Wholesale Revenues ($bn) by Country, 2011
  • Figure 5.14 Alliance Boots Revenue Forecast ($bn), 2011-2022
  • Figure 5.15 Suzuken Revenue Forecast ($bn), 2011-2022
  • Figure 5.16 Medipal Revenue Forecast ($bn), 2011-2022
  • Figure 6.1 Comparison of the Wholesaler and Direct-to-Pharmacy Routes, 2012
  • Figure 7.1 Anti-Counterfeiting Strategies in the US and Europe, 2012

Companies Listed

  • AAH Pharmaceuticals
  • AB Acquisitions Ltd
  • Acofarma (Asociacion Cooperativas Farmaceuticas)
  • Admenta Italia
  • Alfresa Holdings Corp
  • Alfresa Medical Service Corp
  • Alfresa Nikken Sangyo
  • Alliance Boots
  • Alliance Healthcare
  • Alliance Sante
  • Alliance UniChem
  • Amedis-UE AG
  • AmerisourceBergen
  • Anderson Packaging
  • Ando Co.
  • Andreae-Noris Zahn (ANZAG)
  • Apokjeden
  • Australian Pharmaceutical Industries
  • Astellas Pharma
  • Astis Co
  • AstraZeneca
  • Athos Farma
  • Atol Co
  • Bayer
  • Bergen Brunswig
  • Brecon Pharmaceuticals
  • Bristol-Myers Squibb
  • British Association of Pharmaceutical Wholesalers (BAPW)
  • Brocacef Holding
  • Bundesverband des Pharmazeutischen Grosshandel
  • Cahill May Roberts
  • Cardinal Health
  • CareFusion
  • Celesio
  • Center for Medicine in the Public Interest
  • CERP network
  • Chambre Syndicale de la Repartition Pharmaceutique (CSRP)
  • China National Pharmaceutical Group (Sinopharm)
  • Chiyaku Co
  • Cipla
  • Cofares
  • Comifar Group
  • CS Yakuhin Co
  • CVS Caremark
  • Eli Lilly
  • European Association of Euro-Pharmaceutical Companies (EAEPC)
  • European Association of Pharmaceutical Full-line Wholesalers (GIRP)
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Everlth Co.
  • Food and Drug Administration (US FDA)
  • Fukujin Co.
  • Galenica
  • GEHE Pharma Praha
  • GSK
  • Guangzhou Pharmaceuticals Corporation (GP Corp)
  • Healthcare Distribution Management Association (HDMA)
  • Hedef Alliance Holding
  • Hefame
  • Heisei Yakuhin Co.
  • Herba Chemosan
  • Hubei Kyoso Pharmaceutical
  • Humana
  • Huzhong Pharmaceutical Co.
  • HydraPharm
  • Inten
  • Izutsu Pharmaceutical Co.
  • Japanese Pharmaceutical Wholesalers Association
  • Jingu Yakuhin Co.
  • Jointown Pharmaceutical Group
  • Katren
  • Kemofarmacija
  • Kinray
  • Kobashou Co. (Kobayashi Group Company)
  • Kohlberg Kravis Roberts & Co.
  • Kowa Pharmaceuticals Co.
  • Kuraya Sanseido
  • Laboratoria Flandria
  • Libra
  • McKesson
  • Medco Health Solutions
  • Medicaid
  • MEDICEO CORPORATION
  • Medicine Shoppe International
  • MediPal
  • Meisho Co.
  • Merck & Co.
  • Mitsubishi
  • Miyagi Distribution Center
  • Nadro
  • Nakagawa Seikodo Co
  • Nakano Yakuhin Co
  • Napp Pharmaceutical
  • National Health Service (NHS UK)
  • Nomeco
  • Norsk Medisinaldepot
  • Novo Nordisk
  • OCP
  • Odashima
  • Oncology Therapeutics Network
  • Oncoprod
  • Panpharma
  • Parata Systems
  • Pfizer
  • Pharma Belgium
  • Pharmaceutical Security Institute (PSI)
  • PHOENIX Arzeiwarengro?handlung
  • PHOENIX Farmacija
  • PHOENIX Lekarensky
  • PHOENIX Medical Supplies
  • PHOENIX Pharma
  • PHOENIX Pharma Polska
  • PHOENIX Pharmahandel
  • PHOENIX Zdravotocke
  • Polska Grupa Farmaceutyczna
  • Profarma
  • Prosper
  • Protek
  • Ratiopharm
  • Rite Aid Pharmacy
  • Roche
  • Rosta
  • Ryuyaku Co
  • Sanacorp
  • Sanki Corporation
  • Sanofi
  • Seiwa Sangyo Co
  • Shanghai Pharmaceutical Co
  • Shikoku Alfresa Corp
  • Shoyaku Co
  • SIA International
  • Sigma Pharmaceuticals
  • Sincamesp
  • Sinopharm
  • State Food and Drug Administration (SFDA, China)
  • Suzuken
  • Suzuken Iwate Co
  • Suzuken Okinawa Yakuhin Co
  • Target
  • Teva
  • Institute for Pharmaeconomic Research (IPF)
  • The PHOENIX Group
  • The Tamro Group
  • Tjellesen Max Jenne
  • Toho Holdings
  • Torfarm
  • UniChem
  • US Oncology
  • Ushioda Sagokudo Yakuhin Co
  • Vitapharm
  • Walgreens Co.
  • Walmart
  • World Courier Group
  • Wyeth Pharmaceuticals (now part of Pfizer)
  • ZAO Rosta
  • Zuellig Pharma China (Yong Yu)
 

关于我们|联系我们|常见问题|服务项目|购买流程
2005-2013 All rights reserved.京ICP备05069564号-4 京公网安备110108 02010359号
全国服务热线:400-009-0050北京:010-82863481上海:021-64871266

在线客服系统